Etodolac

證據等級: L5

預測適應症: 10 個

Etodolac: From Rheumatoid Arthritis / Osteoarthritis to Ankylosing Spondylitis

One-Sentence Summary

Etodolac is a preferential COX-2 inhibitor NSAID originally established for the treatment of rheumatoid arthritis and osteoarthritis in international markets. The TxGNN model predicts it may be effective for Ankylosing Spondylitis — the highest-ranked clinically actionable indication among ten predictions — with 1 clinical trial and 10 publications currently supporting this direction. Etodolac is not currently registered in India, creating an unmet-access context for this repurposing assessment.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis, osteoarthritis (inferred from published pharmacological literature; no India regulatory record available)
Predicted New Indication	Ankylosing Spondylitis
TxGNN Prediction Score	99.93%
Evidence Level	L3
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data was not retrieved in this evidence pack. Based on published literature included in the evidence, Etodolac is a preferential COX-2 inhibitor belonging to the pyranocarboxylic acid class of NSAIDs. Its primary anti-inflammatory mechanism operates through selective suppression of cyclooxygenase-2, reducing synthesis of prostaglandin E2 (PGE2) — a central mediator of joint inflammation and pain. It is rapidly absorbed after oral administration, with Cmax reached in 1–2 hours and an elimination half-life of 6–8 hours.

Ankylosing spondylitis (AS) is a chronic progressive inflammatory spondyloarthropathy driven by TNF-α/IL-17/IL-23 axis activation, with PGE2 playing a key role in synovial and periosteal inflammation, bone erosion, and new bone formation at entheses. International guidelines from ASAS and EULAR consistently recommend NSAIDs — including preferential COX-2 inhibitors — as the first-line pharmacological therapy for active AS. Etodolac’s mechanism of reducing PGE2 at the spinal and sacroiliac joint level is therefore directly aligned with the therapeutic target in AS.

Crucially, the evidence pack contains direct clinical data for etodolac in AS: large-scale European postmarketing studies involving over 60,000 patients (including AS patients treated by thousands of rheumatologists) and multiple comparative trials versus standard NSAIDs document its efficacy and safety in this disease context. Although dedicated AS-specific phase 3 RCTs for etodolac are absent, the convergence of mechanistic plausibility and real-world clinical evidence establishes a coherent and credible repurposing rationale. The absence of Indian market authorization represents a regulatory gap rather than a scientific one.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05164198	Phase 4	Unknown	448	Multicenter prospective RCT evaluating standard-dose vs reduced-dose TNF inhibitor in stable AS patients; Etodolac is not the trial drug, but the study confirms active clinical research in AS and reflects the disease management landscape where NSAIDs serve as background therapy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1717225	1991	Review	Drugs	Comprehensive pharmacology reappraisal: etodolac demonstrated efficacy in RA, OA, and ankylosing spondylitis; comparable to or better than other NSAIDs across all indications
2146130	1990	Review	Eur J Rheumatol Inflamm	Randomized double-blind parallel-group studies: etodolac (200–300 mg b.i.d.) comparable to naproxen 500 mg b.i.d. in RA, OA, and AS
17694363	1997	Review	Inflammopharmacology	Clinical review confirming COX-2 selectivity as primary mechanism; etodolac widely applied in AS, RA, gout, and OA
2525800	1989	Open Trial	Rev Med Interne	4,947 patients with RA, AS, and OA treated by 974 rheumatologists; etodolac 600 mg/day showed good efficacy and acceptable tolerability profile
2150569	1990	Open Trial (large-scale)	Rheumatology International	Two French open-label studies: Study I (4,947 patients) and Study II (51,355 patients via ~9,000 GPs); safety and efficacy confirmed across RA/AS/OA
2150568	1990	Postmarketing Surveillance	Rheumatology International	8,334 patients across Italy, Switzerland, UK, and France; one study specifically included AS patients; favorable safety profile at standard doses
22071858	2011	Systematic Review	Cochrane Database Syst Rev	Safety of NSAIDs co-administered with methotrexate in inflammatory arthritis (RA, AS, PsA); directly relevant for co-prescribing risk assessment in AS combination therapy
20829199	2011	Expert Consensus / Guideline	Ann Rheum Dis	ASAS recommendations for NSAID intake reporting in axial spondyloarthritis trials; etodolac is included within NSAID equivalence scoring frameworks
21140116	2010	Prospective Open Trial	Singapore Med J	Pamidronate evaluated in NSAID-refractory/intolerant AS patients; indirectly confirms NSAIDs (including COX-2 inhibitors) as standard first-line AS therapy
24449987	2013	Review	IMAJ	Review of indemonstrable axial spondyloarthritis; contextualizes the diagnostic and therapeutic complexity of the AS spectrum relevant to indication definition

India Market Information

Etodolac currently has no registered products in India (0 active licenses, CDSCO data). No authorization number, product name, dosage form, or approved indication text is available from the India regulatory record.

Safety Considerations

Drug Interactions (221 total interactions identified; key interactions listed below):

Severity	Interacting Drugs	Clinical Concern
Moderate	Hydrocortisone, Dexamethasone, Betamethasone, Budesonide, Triamcinolone	Concurrent NSAID + corticosteroid use significantly increases gastrointestinal bleeding and ulceration risk
Moderate	Acetylsalicylic acid (Aspirin)	Combined use amplifies GI mucosal injury and renal perfusion risk
Moderate	Metformin, Glimepiride, Chlorpropamide, Repaglinide	NSAIDs may alter renal clearance of antidiabetics or enhance hypoglycaemic effects
Moderate	Mesalazine, Balsalazide	Potential additive nephrotoxicity with aminosalicylate compounds
Moderate	Potassium citrate, Potassium bicarbonate, Polyethylene glycol (with electrolytes), Picosulfuric acid	Electrolyte handling and renal tubular interactions
Minor	Famotidine, Ranitidine, Cimetidine	H2-receptor antagonists may modestly affect etodolac pharmacokinetics; clinically minor
Minor	Linaclotide	Minor interaction; clinical significance low

Detailed package insert warnings and contraindications are not available in the current evidence pack. Please refer to the official prescribing information for complete safety labelling before clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Etodolac’s preferential COX-2 inhibition is mechanistically aligned with the PGE2-driven inflammation central to ankylosing spondylitis, placing it squarely within the NSAID first-line therapy class recommended by ASAS/EULAR guidelines. Real-world clinical data from large-scale European studies involving tens of thousands of patients — including those with AS specifically — provides an L3 evidence base that justifies advancing beyond pure computational prediction, albeit without dedicated AS-specific Phase 3 RCT data for etodolac.

To proceed, the following is needed:

[Blocking] Obtain and parse the CDSCO/manufacturer package insert to extract complete warnings and contraindications before safety assessment can be finalised
[High] Retrieve confirmed DrugBank MOA and pharmacokinetic parameters to strengthen the mechanistic rationale documentation
[High] Conduct a systematic head-to-head comparison of etodolac against currently India-approved NSAIDs for AS (e.g., indomethacin, naproxen, celecoxib) to define clinical positioning and differentiation
[Medium] Map out India’s CDSCO regulatory pathway for a new NSAID-class NDA or supplemental indication application, given zero existing local registrations
[Medium] Evaluate cardiovascular risk profile in the target AS population, particularly given moderate interactions with corticosteroids (commonly co-prescribed in AS) and aspirin
[Low] Commission or identify a prospective AS-specific controlled study with etodolac as the primary intervention to elevate evidence from L3 to L2, supporting a stronger regulatory dossier
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.